Key result
CYP2C19 loss-of-function alleles predicting clopidogrel resistance occur in ~42% of Māori stroke/TIA patients.
Why the study?
CYP2C19 polymorphisms affect clopidogrel efficacy, and rates of clopidogrel resistance are thought to be high in the New Zealand Māori population, prompting measurement of resistance rates in Māori patients and patients with clopidogrel failure presenting with ischaemic stroke or TIA.
Observational (n=102)
Yes
Answers are grounded in this paper and cite their sources.
High rates of CYP2C19 loss-of-function alleles in New Zealand Māori stroke/TIA patients (42%) and patients with clopidogrel failure (35%) support broader genetic testing to guide alternative antiplatelet therapy such as ticagrelor.
Background Cytochrome (CYP) 2C19 polymorphisms affect the efficacy of clopidogrel. Rates of clopidogrel resistance are thought to be high in the New Zealand Māori population. We measured rates of clopidogrel resistance in two groups experiencing ischaemic stroke/TIA in Northland/Te Tai Tokerau: Māori patients and patients already taking clopidogrel (‘clopidogrel failure’).Methods Observational study of existing clinical and demographic data from people seen in Northland hospitals between March 2025 and April 2026 with ischaemic stroke or TIA falling into two groups: Māori ethnicity or clopidogrel failure. Some patients were recorded in both groups. We collected data on CYP2C19 status to determine predicted response or resistance to clopidogrel.Results A total of 102 patient records were analysed: 71 in the Māori group and 43 in the clopidogrel failure group, with 12 patients in both groups. Median ages were 65 years and 73 years in the Māori and clopidogrel failure groups respectively, with 28/71 (39%) and 26/43 (61%) males, respectively. Among Māori patients, 30/71 (42%) had loss-of-function alleles (predicting intermediate to poor response to clopidogrel). Among those patients having an event while taking clopidogrel, 15/43 (35%) had loss-of-function alleles.Conclusion In this targeted but highly relevant population, resistance to clopidogrel is high. These patients are unlikely to experience benefit from clopidogrel following stroke/TIA. With the introduction of ticagrelor in New Zealand to treat high-risk TIA and minor stroke in clopidogrel-resistant patients, broader testing for CYP2C19 status is crucial to ensure the right treatment for the right patient.
No takes yet. Share an insight, caveat, or question.
Bickler et al. (2026) conducted an observational in Ischaemic stroke or TIA (n=102). CYP2C19 status testing in Māori ethnicity and clopidogrel failure groups was evaluated on CYP2C19 loss-of-function alleles predicting clopidogrel resistance. CYP2C19 loss-of-function alleles predicting clopidogrel resistance were present in 42% (30/71) of Māori stroke/TIA patients and 35% (15/43) of clopidogrel failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: